Berenberg cuts target for Fresenius Medical Care stock to EUR 42.00

Published on 10/01/2026 at 13:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached EUR 4.86 billion in the quarter ended June 30, 2026. Fresenius Medical Care stock costs EUR 39.71 on October 1, 2026 versus EUR 39.56.

Moderner Dialyseraum mit Hämodialysegeräten und Patientenliegen bei Tageslicht — Ein fotorealistisches Bild eines modernen Dialyseraums mit mehreren Hämodialysegeräten und Patientenliegen in Reihe, ruhigem Tageslicht durch große Fenster – typisch für die Behandlungszentren von Fresenius Medical Care AG (ISIN DE0005785802), Illustration mit AI erstellt.

Fresenius Medical Care (DE0005785802) was trading at EUR 39.71 at Lang & Schwarz on October 1, 2026 at 1:30 p.m. CEST, up 0.38 percent from the prior close of EUR 39.56. The latest analyst move came from Berenberg, which cut its rating and price target on September 29, 2026.

Berenberg cuts its target

According to Markets Insider, Berenberg downgraded Fresenius Medical Care from Buy to Hold and lowered its target from EUR 60.00 to EUR 42.00 on September 29, 2026. The note linked a potential share re-rating to evidence of positive US kidney-care treatment growth, while its 2030 margin forecast of 12.00 percent remained below management's mid-teens ambition.

The target cut is the clearest near-term counterweight to the company's operating progress. At EUR 39.71, the new EUR 42.00 target lies 5.77 percent above the Lang & Schwarz price, leaving a narrower valuation gap than the previous target implied.

Second-quarter numbers stay strong

Markets Insider reported that revenue reached EUR 4.86 billion and net income EUR 218.00 million in the quarter ended June 30, 2026. The figures give the analyst debate a firm operating base, even as treatment volumes remain the key issue in Berenberg's assessment.

The company said its second-quarter operating result grew 23.00 percent year over year and that its 5008X CAREsystem had reached 227 US clinics with more than 600,000 treatments. The investor-relations page also states that Fresenius Medical Care confirmed its 2026 outlook, while the first-half operating result followed the expected full-year pattern.

Cyber incident precedes November results

Fresenius Medical Care said in a company statement dated September 22, 2026 that unauthorized access affected a limited number of internal systems. The company said medical devices, patient care, manufacturing operations and business continuity remained unaffected, while cybersecurity experts and law enforcement were engaged.

The investor calendar lists November 3, 2026 for publication of the third-quarter 2026 results and the conference call, according to Fresenius Medical Care. That date puts treatment growth, margin delivery and the cyber investigation on the next scheduled reporting agenda.

FMC stock remains below its high

FMC stock was 17.03 percent below its 52-week high of EUR 47.86 on October 1, 2026, with market capitalization at EUR 10.6 billion. The Lang & Schwarz quote stood at EUR 39.71 at 1:30 p.m. CEST, plus 0.38 percent versus EUR 39.56. The further course of trading is shown by the continuously updated real-time quote of Fresenius Medical Care stock.